Open AccessModified ticagrelor loading doses according to the vasodilator-stimulated phosphoprotein phosphorylation index improve the clinical outcome in ST-elevation myocardial infarction patients with high on-treatment platelet reactivity
Author(s) -
Yaling Liu,
Sheng Kang,
Xin Li,
ZhaoTie Liu,
Yang Gao,
Xiaodong Wang
Publication year - 2023
Publication title -
cardiology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.573
H-Index - 33
eISSN - 1897-5593
pISSN - 1898-018X
DOI - 10.5603/cj.a2021.0105
Subject(s) - medicine , ticagrelor , percutaneous coronary intervention , myocardial infarction , cardiology , timi , loading dose , mace , hazard ratio , confidence interval
Current guidelines recommend a standard ticagrelor loading dose (LD) in ST-segment elevation myocardial infarction (STEMI) patients. However, antiplatelet therapy in STEMI patients at high risk of thrombotic events is suboptimal. The study was conducted to validate whether vasodilatorstimulated phosphoprotein (VASP)-guided ticagrelor dosing individual therapy may result in more effective platelet inhibition and better clinical outcomes.